Why is Dr Lal Pathlabs falling/rising?

As of 25-Jul, Dr Lal Pathlabs Ltd is currently priced at 3,074.30, reflecting a decrease of 20.7 points or 0.67%. The stock has recently underperformed its sector by 1.22% and has experienced a trend reversal, falling after three consecutive days of gains. Despite this decline, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend over a longer period. In terms of returns, the stock has shown a 2.45% increase over the past week and an 11.51% increase over the past month, while it has generated a modest 2.58% return over the past year. Positive factors include high management efficiency with a return on equity (ROE) of 20.50% and significant growth in profit after tax (PAT) over the last six months. However, concerns about poor long-term growth and a high valuation relative to its peers may be contributing to the recent price decline.
In the broader market context, Dr Lal Pathlabs has outperformed the Sensex over the past week and month, while the benchmark has shown a slight decline of 0.36% over the past week and a more significant drop of 1.56% over the past month. This indicates that while the stock is currently facing a downturn, it has been relatively resilient compared to the overall market performance. The high institutional holdings at 39.6% suggest that informed investors are backing the stock, which may provide some support against broader market pressures. However, the stock's recent performance, combined with concerns about its long-term growth potential, may be influencing investor sentiment negatively at this time.